Jeito Capital, Prominent Biotech Investor, Raises $1.2B for Next Fund

Why It Matters

The fund injects critical growth capital into Europe’s biotech sector, bolstering drug development pipelines and signaling strong investor belief despite a broader funding slowdown.

Key Takeaways

• Jeito II fund totals €1 billion (~$1.2 billion) for European biotech.
• Fund aims to back 15‑20 clinical-stage companies, up to €150 million each.
• Past Jeito exits include $1.3 billion EyeBio sale to Merck.
• European biotech fundraising slows, Q1 2026 total $3.2 billion.
• Jeito targets obesity, oncology, autoimmune therapies with new capital.

Pulse Analysis

Jeito Capital’s €1 billion raise marks a watershed moment for European biopharma financing. By surpassing the €534 million haul of its inaugural fund, Jeito II demonstrates that independent venture firms can marshal capital comparable to U.S. counterparts. The fund’s strategy—deploying up to €150 million per company—allows portfolio firms to progress through costly Phase II and III trials without diluting ownership excessively. This depth of backing is especially valuable in therapeutic areas like obesity and autoimmune disease, where development costs often exceed $200 million per indication.

The European biotech ecosystem has matured rapidly, as evidenced by Jeito’s three marquee exits: Neogene’s $200 million sale to AstraZeneca, EyeBio’s $1.3 billion deal with Merck, and Hi‑Bio’s $1.15 billion acquisition by Biogen. These transactions validate the region’s ability to generate globally competitive drug candidates and provide liquidity for investors. Moreover, Jeito’s continued support for innovators such as Callio Therapeutics and ReproNovo underscores a commitment to diversified pipelines, from antibody‑drug conjugates to women’s‑health solutions, reinforcing Europe’s growing reputation as a hub for specialty therapeutics.

Despite Jeito’s optimism, the broader venture landscape shows a contraction, with Q1 2026 biotech funding dropping to $3.2 billion from $4.8 billion in 2025. Yet median round sizes remain stable around $85 million, suggesting that while fewer deals are being made, investors are still willing to fund sizable, high‑potential programs. Jeito’s sizable fund therefore serves as a counter‑balance, offering a reliable source of capital that can sustain long‑term research pipelines and potentially attract additional investors back into the European market as pipeline successes accumulate.